MF

Mathias Frederiksen

Principal @ Novartis Venture Fund

Basel, Basel

VC

Invests in

Stages:

Series A
Seed

  • Min Investment:

    $5,000,000.00

  • Max Investment:

    $10,000,000.00

  • Target Investment:

    $7,500,000.00

Skills

Start-up Ventures
Corporate Venture Capital
Company build
Venture Capital
Venture Financing
Finance
Epigenetics
Medicinal Chemistry
Drug Design
Organic Synthesis
Drug Discovery
Life Sciences
Proteomics
Cell Based Assays
Organic Chemistry
Signal Transduction
Target Identification
Lifesciences
Pharmaceutical Industry
Lead Change

Education

Investments

FundaMental Pharma

Seed

Total Funding: $13M

Work Experience

Novartis Venture Fund

2022

  • Principal

    2023

  • Associate

    2022 - 2023

    Discover and nurture biotech start-ups from seed to IPO.

Exsilio Therapeutics

2024

  • Board Observer

    2024

FundaMental Pharma

2023

  • Director Board of Directors

    2023

    Helping FMP to realize breakthrough therapies in neurodegeneration

Stealth oncology company

2023

  • Board Observer

    2023

UZH Life Sciences Fund

2022

  • Board Observer

    2022

    The UZH Life Sciences Fund is a partnership between the UZH Foundation and Novartis Venture Fund to seed UZH spinouts in the field of life sciences.

LoQus23 Therapeutics Ltd

2022

  • Board Observer

    2022

    Helping LOQUS23 amazing team to bring small molecule therapeutics to patients suffering from triplet expansion disorders like Huntington's Disease.

Novartis Institutes for BioMedical Research (NIBR)

2005 - 2022

  • Associate Director and Group Leader Chomatin Chemical Biology

    2020 - 2022

    Directing a research program aimed at elucidating the role of epigenetic regulation in human disease to uncover novel paradigms for chromatin-focused drug discovery.

  • Senior Investigator II

    2018 - 2020

    Group leader Chromatin Chemical Biology: Directing a research program aimed at elucidating the role of epigenetic regulation in human disease to uncover novel paradigms for chromatin-focused drug discovery.

  • Senior Investigator I

    2014 - 2018

    Lab-head Global Discovery Chemistry - Chemogenetics Chemical proteomics, new target discovery, new chemical technologies at the interface of chemistry and biology.

  • Investigator III

    2010 - 2014

    Lab-head Global Discovery Chemistry - Chemogenetics Chemical proteomics, new target discovery, new chemical technologies at the interface of chemistry and biology.

  • Research Investigator II

    2007 - 2009

    Lab-head Global Discovery Chemistry - Neuroscience Development of novel therapeutic agents against Neurodegenerative disease.

  • Research Investigator I

    2005 - 2007

    Lab-head Global Discovery Chemistry - Neuroscience Development of novel therapeutic agents against Neurodegenerative disease.

Stanford University

2003 - 2004

  • Post-doctoral Research Investigator

    2003 - 2004

    Research Fellow in the laboratories of Professor Barry Trost, working on Pd-catalyzed asymmetric alkylation reactions and total synthesis. Funded by GSK Postdoctoral Fellowship

Imperial College London

1998 - 2002

  • PhD Candidate

    1998 - 2002

    PhD candidate in the laboratories of Professor Tony Barrett. Focus of research was development of macrolactonization protocols amenable to solid-phase synthesis of macrolides as well as development of other solid-phase methodologies. Funded by Norwegian Research Council